Amgen’s Otezla Hits Primary Goal in PIII of Japanese PPP Patients

Amgen’s psoriasis therapy Otezla (apremilast) achieved the primary endpoint in a PIII trial targeting 176 Japanese patients with palmoplantar pustulosis (PPP), according to the latest data. The primary endpoint was the ratio of patients who saw an improvement of 50%...read more